



COPY OF PAPERS
ORIGINALLY FILED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT

Applicant: John A. Lust et al. Examiner: A. Beckerleg, Ph.D.
Serial No.: 09/730,374 Group Art Unit: 1632
Filed: December 5, 2000 Docket: 150.188US2
Title: USE OF GENETICALLY ENGINEERED ANTIBODIES TO CD38 TO TREAT
MULTIPLE MYELOMA

AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

RECEIVED

AUG 22 2002

TECH CENTER 1600/2900

In response to the "Communication" from the Examiner mailed July 15, 2002, please amend the above-identified application as follows:

In the Specification

Please enter the substitute SEQUENCE LISTING into the specification.

Please make the paragraph substitutions indicated in the appendix entitled Clean Version of Amended Specification Paragraphs. The specific changes incorporated in the substitute paragraphs are shown in the following marked-up versions of the original paragraphs:

Please amend the paragraph beginning at page 6, line 10 of the specification as follows:

Figure 6 depicts the nucleotide sequence (SEQ ID NO:1) and its complementary sequence (SEQ ID NO:5) encoding a scFV (SEQ ID NOs:2-4) which specifically binds CD38.

Remarks

This Amendment and the above-referenced substitute SEQUENCE LISTING are filed to conform the above-referenced application to the requirements of 37 C.F.R. §§ 1.821 - 1.825. In accordance with 37 C.F.R. § 1.821(e), a copy of the above-submitted substitute SEQUENCE LISTING in ASCII computer readable form is also submitted on even date herewith to the U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington VA 22202. The contents